Article in The Journal of experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
Fanny SaidouneDepartment of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0009-0002-9776-6370
Danyel Lee *St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.ORCID 0000-0003-3124-0245
Jeremy Di Domizio *Department of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-6281-3918
Corentin Le Floc'h *St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.ORCID 0009-0007-0590-0437
Raphael JeneltenDepartment of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-0122-8918
Jérémie Le PenLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID 0000-0001-7025-9526
Vincent BondetTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0002-6534-0984
Ana JoncicDepartment of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0009-0005-3845-4504
Marie-Anne MorrenDepartment of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-4860-5194
Vivien BéziatSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-4020-824X
Shen-Ying ZhangSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-9449-3672
Emmanuelle JouanguySt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-7358-9157
Darragh DuffyTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0002-8875-2308
Charles M RiceLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID 0000-0003-3087-8079
Curdin ConradDepartment of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-2547-3440
Jacques FellaySchool of Life Sciences, Ecole Polytechnique Fédérale de Lausanne , Lausanne, Switzerland.ORCID 0000-0002-8240-939X
Jean-Laurent Casanova *St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-7782-4169
Michel Gilliet *Department of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-4609-3762
Ahmad Yatim *Department of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-4859-4085
Funding
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
Understanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI RAVETCH, JEFFREY VICTOR · 2014 to 2023
$26.0M
Type I interferon-stimulated genes and the antiviral immune responseR01AI091707 · NIAID · ROCKEFELLER UNIVERSITY · PI RICE, CHARLES M · 2011 to 2020
$5.5M
Inborn errors of immunity in patients with life-threatening COVID-19R01AI163029 · NIAID · ROCKEFELLER UNIVERSITY · PI CASANOVA, JEAN-LAURENT, ZHANG, QIAN · 2021 to 2025
$3.7M
Tracking SARS-CoV-2 one molecule at a time: Spatiotemporal investigation of coronavirus replication dynamics and host response in single cells in vitro and in vivoR01AI161444 · NIAID · ROCKEFELLER UNIVERSITY · PI Charles M Rice · 2022 to 2026
$3.1M
Agence Nationale de la Recherche ANR-10-IAHU-01Battersea & Bowery Advisory GroupBawd FoundationCancer Research InstituteCarson Family Foundation CRI5801Clinical and Translational Science Award UL1TR001866European Academy of Dermatology and VenereologyEuropean Molecular Biology Organization ALTF 380-2018European Society for ImmunodeficienciesEuropean Union's Horizon 2020 824110Fisher Center for Alzheimer's Research FoundationFondation du SouffleFrench Foundation for Medical ResearchFrench Ministry of Higher Education, Research, and Innovation MESRI-COVID-19General Atlantic FoundationGeorge Mason UniversityG. Harold and Leila Y. Mathers Charitable FoundationGrandir - Fonds de solidarité pour l'enfanceHORIZON-HLTH-2021-DISEASE-04 101057100Howard Hughes Medical InstituteINCaInstitut National de la Santé et de la Recherche MédicaleITMO Cancer of AviesanJPB FoundationLeenaards FoundationMeyer FoundationNCATS NIH HHS UL1 TR001866NIAID NIH HHS R01 AI091707NIAID NIH HHS R01 AI161444NIAID NIH HHS R01 AI163029NIAID NIH HHS U19 AI111825NIH HHS R01AI163029Rockefeller UniversitySchlumberger FoundationSCOR Corporate Foundation for ScienceSquare FoundationSt. Giles FoundationSwiss National Science Foundation 4078P0_198470Thrasher Research FundUniversité de ParisUniversité Paris-Saclay
6 · The paper itself
Abstract
Outbreaks of chilblains were reported during the COVID-19 pandemic. Given the essential role of type I interferon (I-IFN) in protective immunity against SARS-CoV-2 and the association of chilblains with inherited type I interferonopathies, we hypothesized that excessive I-IFN responses to SARS-CoV-2 might underlie the occurrence of chilblains in this context. We identified a transient I-IFN signature in chilblain lesions, accompanied by an acral infiltration of activated plasmacytoid dendritic cells (pDCs). Patients with chilblains were otherwise asymptomatic or had mild disease without seroconversion. Their leukocytes produced abnormally high levels of I-IFN upon TLR7 stimulation with agonists or ssRNA viruses-particularly SARS-CoV-2-but not with DNA agonists of TLR9 or the dsDNA virus HSV-1. Moreover, the patients' pDCs displayed cell-intrinsic hyperresponsiveness to TLR7 stimulation regardless of TLR7 levels. Inherited TLR7 or I-IFN deficiency confers a predisposition to life-threatening COVID-19. Conversely, our findings suggest that enhanced TLR7 activity in predisposed individuals could confer innate, pDC-mediated, sterilizing immunity to SARS-CoV-2 infection, with I-IFN-driven chilblains as a trade-off.
Indexed as
ChilblainsCOVID-19Dendritic CellsInterferon Type IToll-Like Receptor 7AdultFemaleHumansMaleMiddle AgedPandemicsSARS-CoV-2Interferon Type ITLR7 protein, humanToll-Like Receptor 7
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Enhanced TLR7-dependent production of type I interferon by pDCs underlies pandemic chilblains. · full record | OpenQuestion